top of page

Etcembly's T-cell engager featured in Inside Precision Medicine

Aug 22, 2023
1 min read

The announcment of Etcembly's picomolar affinity bispecific T-cell engager targeting PRAME, ETC-101, has been covered by inside Precision Medicine - Generative AI Used to Develop T Cell Cancer Immunotherapy

Recent Posts

Etcembly's CEO, Michelle Teng, speaks with Ian Kahn "The Futurist' about the future of healthcare innovation and how AI is rewriting the cure for cancer

Etcembly's CEO, Michelle Teng, speaks with Ian Khan 'The Futurist' about the future of healthcare innovation and how AI is rewriting the cure for cancer

Say hello to EMLy™ Co-pilot – our AI driven biologics discovery platform - where conversations turn bright ideas into novel therapeutics.

Say hello to EMLy™ Co-pilot – our AI driven biologics discovery platform - where conversations turn bright ideas into novel therapeutics.

Say hello to EMLy Co-pilot, the AI biologics discovery platform built on an extensive immune database

Say hello to EMLy Co-pilot, the AI biologics discovery platform built on an extensive immune database

Comments

bottom of page